Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer

OBJECTIVES: Primary * To determine the safety, tolerability, and recommended phase II dose of sorafenib tosylate when administered in combination with vinorelbine ditartrate in women with stage IV adenocarcinoma of the breast. (Phase I) * To evaluate the 4-month progression-free survival rate in patients treated with this regimen at the maximum tolerated dose. (Phase II) Secondary * To determine time to treatment failure in these patients. * To determine the response rate in these patients. * To determine the overall survival and progression-free survival of these patients. * To evaluate the toxicity profile of this regimen. OUTLINE: This is a phase I, dose-escalation study of sorafenib tosylate followed by a phase II study. Patients receive oral sorafenib tosylate on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically.